KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsShares Issued
Ratios

Nektar Therapeutics (NKTR) Accumulated Depreciation & Amortization (2016 - 2024)

Historic Accumulated Depreciation & Amortization for Nektar Therapeutics (NKTR) over the last 10 years, with Q4 2024 value amounting to $4.1 million.

  • Nektar Therapeutics' Accumulated Depreciation & Amortization fell 4142.86% to $4.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.1 million, marking a year-over-year decrease of 4142.86%. This contributed to the annual value of $4.1 million for FY2024, which is 4142.86% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Accumulated Depreciation & Amortization of $4.1 million as of Q4 2024, which was down 4142.86% from $7.0 million recorded in Q4 2023.
  • In the past 5 years, Nektar Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $139.6 million in Q2 2022 and a low of $4.1 million during Q4 2024
  • For the 5-year period, Nektar Therapeutics' Accumulated Depreciation & Amortization averaged around $45.9 million, with its median value being $12.5 million (2020).
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 1363.64% in 2020, then tumbled by 4262.3% in 2023.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Accumulated Depreciation & Amortization stood at $12.5 million in 2020, then increased by 4.0% to $13.0 million in 2021, then dropped by 6.15% to $12.2 million in 2022, then crashed by 42.62% to $7.0 million in 2023, then tumbled by 41.43% to $4.1 million in 2024.
  • Its Accumulated Depreciation & Amortization was $4.1 million in Q4 2024, compared to $7.0 million in Q4 2023 and $12.2 million in Q4 2022.